A trial of oral Semaglutide in patients with early Alzheimer’s Disease who also exhibit MRI evidence of cerebrovascular disease (EVOKE PLUS)
Disease/Condition: Alzheimer’s disease
Enrollment Opens: 01-31-2022
Enrollment Closes: TBD
This is a clinical trial looking at the efficacy and safety of oral Semaglutide (GLP-1 agonist) versus placebo on the change in cognition and function in patients with MCI (Mild Cognitive Impairment) or mild dementia, WITH corresponding evidence of cerebrovascular disease or “Mixed Dementia”
Study ID: NovoNordisk NN6536-4725
To Enroll: Please call (503) 228-2273 (CARE) to schedule free memory lost testing and evaluation. Or contact http://www.summitresearchnetwork.com for additional informaton.
Posted by: Summit Headlands LLC | http://www.summitresearchnetwork.com